Therefore, including PD-1/PD-L1 pathway inhibition in PTEN-mutated GBM, together with TAM targeting, could be an efficient treatment strategy, as suggested by the combinatorial effects of PI3K and CSF-1R inhibitors to reprogram macrophages toward an anti-tumorigenic phenotype (110). Here, CSF1R is linked to glioblastoma.